Close Menu

Scienion

Boston-based Cellink will acquire the German firm for €40 million in cash and 2,814,032 newly issued shares valued at €40 million at a price of SEK 146.6 per share.

The companies will jointly offer services and equipment solutions for the development, high-volume manufacture, and launch of multiplexed in vitro diagnostics.

The firms will collaborate on creating and co-marketing array technologies for research and clinical diagnostics.

The partners will develop multiplex tests to detect human pathogens in 75 minutes on Grenier's PCR-based Genspeed Test System.

The partners will launch the alliance by developing a colorimetric reader system for multiplexed lateral flow microarrays.

The partners will combine the sciFlexarrayer with Anteo's reagents to improve the functionality and shelf-life of activated glass and polymer slides and other arrays.

QuantuMDx will use Scienion's ultra-low-volume liquid handling technologies in its Q-Poc handheld molecular diagnostic device.

NEW YORK (GenomeWeb) — Scienion and Genomica today announced the CE IVD marking and launch of their jointly developed multiplex molecular assay for sexually transmitted infections.

NEW YORK (GenomeWeb) – The Institute for Global Food Security, MBio Diagnostics, and Scienion today announced they will combine their technologies to create tools to monitor marine toxins.

NEW YORK (GenomeWeb) – The AIT Austrian Institute of Technology, BioVendor, and Scienion announced today a partnership to develop an in vitro diagnostic test for the early detection of colon cancer.

Pages

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.